Vanguard Group Inc. reduced its holdings in Twist Bioscience Co. (NASDAQ:TWST – Free Report) by 2.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,475,322 shares of the company’s stock after selling 115,652 shares during the period. Vanguard Group Inc. owned approximately 9.47% of Twist Bioscience worth $201,820,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Federated Hermes Inc. acquired a new position in Twist Bioscience during the 3rd quarter valued at $29,000. Trexquant Investment LP raised its position in shares of Twist Bioscience by 212.9% during the third quarter. Trexquant Investment LP now owns 64,363 shares of the company’s stock valued at $1,304,000 after buying an additional 43,794 shares during the last quarter. Gotham Asset Management LLC lifted its stake in shares of Twist Bioscience by 253.2% in the third quarter. Gotham Asset Management LLC now owns 42,598 shares of the company’s stock valued at $863,000 after buying an additional 30,537 shares during the period. Seven Eight Capital LP acquired a new stake in Twist Bioscience during the third quarter worth about $306,000. Finally, Graham Capital Management L.P. bought a new position in Twist Bioscience during the third quarter valued at about $304,000.
Twist Bioscience Stock Performance
Twist Bioscience stock opened at $47.32 on Wednesday. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $55.26. The firm has a market cap of $2.76 billion, a P/E ratio of -14.08 and a beta of 1.80. The business’s fifty day moving average is $44.55 and its two-hundred day moving average is $38.58.
Insider Activity at Twist Bioscience
In other Twist Bioscience news, CEO Emily M. Leproust sold 4,163 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $154,572.19. Following the transaction, the chief executive officer now directly owns 509,986 shares in the company, valued at approximately $18,935,780.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Twist Bioscience news, CEO Emily M. Leproust sold 2,408 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total value of $123,602.64. Following the transaction, the chief executive officer now directly owns 507,578 shares of the company’s stock, valued at $26,053,978.74. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 4,163 shares of Twist Bioscience stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $154,572.19. Following the sale, the chief executive officer now directly owns 509,986 shares of the company’s stock, valued at approximately $18,935,780.18. The disclosure for this sale can be found here. Insiders sold a total of 17,246 shares of company stock valued at $706,593 over the last quarter. Corporate insiders own 3.92% of the company’s stock.
Analyst Ratings Changes
Several research analysts recently commented on TWST shares. Evercore ISI raised their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Barclays lifted their target price on shares of Twist Bioscience from $45.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, June 28th. Robert W. Baird increased their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Guggenheim began coverage on Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price objective on the stock. Finally, Scotiabank increased their target price on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a report on Monday, May 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Twist Bioscience has an average rating of “Buy” and a consensus target price of $48.50.
Check Out Our Latest Report on Twist Bioscience
Twist Bioscience Company Profile
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Further Reading
- Five stocks we like better than Twist Bioscience
- What Are Trending Stocks? Trending Stocks Explained
- RXO Shares Surge Following New Acquisition Deal
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Trading Halts Explained
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWST – Free Report).
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.